COVID-19 Response (VI): Oral DNA Vaccine Development
$2,821,081.00
Grant Value
2020-21
Fiscal Year
Description
The goal of this project is to develop and clinically evaluate an oral, room temperature stable DNA vaccine candidate for SARS-CoV2. The project will involve the advancement of the bacTRL-Spike COVID-19 vaccine candidate through preclinical development, process development manufacturing scale-up, and first-in-human clinical testing.
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Grant Details
Recipient
Symvivo Corporation
Location
Burnaby, BC V5G 4X4
Agreement Details
Number: 956763
Reference: 172-2020-2021-Q2-956763
Timeline
Start: Sept. 4, 2020
End: March 31, 2021
Program
Industrial Research Assistance Program ? Contributions to Firms
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or …
Sector
Professional, scientific and technical services (541710)
Your Contribution
Calculate how much you personally contributed to this grant through your taxes.
Calculate My Share